Trump administration courts investors in broad effort to combat rising health care costs

The Trump administration is battling rising health costs by going after the incentives that help drive higher prices. That's the idea at the heart of the new payment model for high-priced drugs, and the driving force behind a new initiative to engage health care investors about how reimbursement policies are fueling funds for new treatment options. "We have certain initiatives that we do where we depend on innovation," Eric Hargan, deputy secretary for Health and Human Services, told CNBC.